

**Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma,  
irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA  
(Albers *et al.*)**

**Contents**

**Supplementary Table S1** Rate ratio of clinically significant exacerbations by body weight in the MENSA and DREAM studies (intent-to-treat population).

**Supplementary Table S1** Rate ratio of clinically significant exacerbations by body weight in the MENSA and DREAM studies (intent-to-treat population).

|   | Body weight categories    |                           |                           |                           |
|---|---------------------------|---------------------------|---------------------------|---------------------------|
|   | ≤60 kg                    | >60–75 kg                 | >75–90 kg                 | >90 kg                    |
| <b>Exacerbation rate ratio, 95% CI, mepolizumab/placebo</b> |                           |                           |                           |                           |
| <b>DREAM study</b>  |                           |                           |                           |                           |
| Mepolizumab 75 mg IV  | n=25<br>0.67 (0.39, 1.14) | n=47<br>0.57 (0.33, 0.96) | n=52<br>0.58 (0.34, 0.98) | n=29<br>0.25 (0.13, 0.49) |
| Mepolizumab 250 mg IV                                       | n=25<br>0.46 (0.25, 0.85) | n=44<br>1.09 (0.68, 1.74) | n=43<br>0.40 (0.23, 0.71) | n=40<br>0.44 (0.26, 0.75) |
| Mepolizumab 750 mg IV                                       | n=18<br>0.21 (0.09, 0.48) | n=41<br>0.69 (0.41, 1.16) | n=48<br>0.45 (0.26, 0.79) | n=49<br>0.52 (0.32, 0.87) |
| <b>MENSA study</b>  |                           |                           |                           |                           |
| Mepolizumab 100 mg SC                                       | n=41<br>0.32 (0.14, 0.75) | n=67<br>0.39 (0.23, 0.65) | n=55<br>0.58 (0.34, 1.00) | n=31<br>0.64 (0.33, 1.21) |
| Mepolizumab 75 mg IV  | n=40<br>0.48 (0.20, 1.16) | n=50<br>0.36 (0.20, 0.66) | n=63<br>0.73 (0.44, 1.23) | n=38<br>0.62 (0.34, 1.13) |

DREAM and MENSA were randomized, multicentre, double-blind, placebo-controlled trials.[1,2] Patients had a history of ≥2 exacerbations requiring systemic corticosteroid treatment in the previous year and evidence of eosinophilic inflammation. Patients enrolled in DREAM were randomised (1:1:1:1) to receive mepolizumab 75 mg IV (n=154), mepolizumab 250 mg IV (n=152), mepolizumab 750 mg IV (n=156) or placebo (n=159), plus standard of care, every 4 weeks for 52 weeks (totalling 13 infusions). Patients enrolled in MENSA were randomised (1:1:1) to receive mepolizumab 75 mg IV (n=191), mepolizumab 100 mg SC (n=194) or placebo (n=191), plus standard of care, every 4 weeks for 32 weeks.

CI, confidence interval; IV, intravenous; SC, subcutaneous.

## References

1. Ortega HG, Liu MC, Pavord ID, *et al.* Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014;371:1198-207.
2. Pavord ID, Korn S, Howarth P, *et al.* Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *The Lancet* 2012;380:651-59.